Sorry, you need to enable JavaScript to visit this website.

This site is intended for US healthcare professionals only.

BREXAFEMME® (ibrexafungerp, 150 mg per tablet) Logo

This site is intended for US healthcare professionals only.

WATCH THE MOA
✕

A cure that’s well-tolerated?

That’s BREXAFEMME1,2

A cure that’s well-tolerated?

That’s BREXAFEMME1,2

Well-tolerated across a broad range of patients1

Table featuring the most common adverse reactions from BREXAFEMME® (ibrexafungerp tablets) in the VANISH trials
Table featuring the most common adverse reactions from BREXAFEMME® (ibrexafungerp tablets) in the VANISH trials

  • bullet-point-iconThe most common adverse reactions reported were GI side effects, with the majority being mild and transient2
  • bullet-point-icon2 out of 545 patients studied in Phase 3 clinical trials discontinued treatment with BREXAFEMME due to dizziness (1 patient) and vomiting (1 patient)1
  • bullet-point-iconNo QTc interval prolongation at >5 times the concentration of the indicated dose1
  • bullet-point-iconBREXAFEMME is contraindicated during pregnancy and in patients with a history of hypersensitivity to ibrexafungerp1
  • bullet-point-iconThere is a pregnancy safety study for BREXAFEMME. If BREXAFEMME is inadvertently administered during pregnancy or if pregnancy is detected within 4 days after a patient receives BREXAFEMME, pregnant women exposed to BREXAFEMME and healthcare providers should report pregnancies to SCYNEXIS, Inc., at 1-888-982-SCYX (7299)1

*Includes abdominal pain, abdominal pain upper, abdominal pain lower, and abdominal discomfort.1

†Includes dizziness and postural dizziness.1

GI=gastrointestinal.

tick_image__alt

Prescribe BREXAFEMME
with confidence.

Deliver the cure with
one-day oral dosing.1,2


See Dosing

You’ve prescribed the cure.1,2
Now it’s easy for your patients to find it.

See Pharmacy Finder

MOST COMMON ADVERSE REACTIONS (INCIDENCE ≥2%)1

  BREXAFEMME
(N=545)		 PLACEBO
(N=275)
Diarrhea 16.7% 3.3%
Nausea 11.9% 4.0%
Abdominal Pain* 11.4% 5.1%
Dizziness† 3.3% 2.5%
Vomiting 2.0% 0.7%
BREXAFEMME
(N=545)
Diarrhea
16.7%
Nausea
11.9%
Abdominal Pain*
11.4%
Dizziness†
3.3%
Vomiting
2.2%
 
PLACEBO
(N=275)
Diarrhea
3.3%
Nausea
4.0%
Abdominal Pain*
5.1%
Dizziness†
2.5%
Vomiting
0.7%

Includes abdominal pain, abdominal pain upper, abdominal pain lower, and abdominal discomfort.

Includes dizziness and postural dizziness.

SAY NO MORE to vaginal yeast infections.
Prescribe BREXAFEMME today.

Request a Rep
✕

SAY NO MORE to vaginal yeast infections. Prescribe BREXAFEMME today.

Request a Rep
✕

Indication

BREXAFEMME® is a triterpenoid antifungal indicated for Treatment of VVC and Reduction in the incidence of recurrent vulvovaginal candidiasis (RVVC) in adult and post-menarchal pediatric females.

Important Safety Information

Risk of Embryo-fetal Toxicity

  • BREXAFEMME is contraindicated in pregnancy because it may cause fetal harm based on findings from animal reproductive studies
  • For females of reproductive potential, verify that the patient is not pregnant prior to initiating BREXAFEMME treatment. Reassessing pregnancy status prior to each dose is recommended when BREXAFEMME is used monthly for 6 months for reduction in the incidence of recurrent vulvovaginal candidiasis (RVVC)
  • Advise females of reproductive potential to use effective contraception during treatment of vulvovaginal candidiasis (VVC) and throughout the 6-month treatment period for reduction in the incidence of RVVC with BREXAFEMME and, for 4 days after the last dose
  • BREXAFEMME is contraindicated in patients with a history of hypersensitivity to ibrexafungerp
  • When administering BREXAFEMME with strong CYP3A inhibitors, the dose of BREXAFEMME should be reduced to 150 mg twice a day for one day. Administration of BREXAFEMME with strong CYP3A inducers should be avoided
  • Most common adverse reactions observed in clinical trials (incidence ≥2%) of VVC were diarrhea, nausea, abdominal pain, dizziness, and vomiting. Most common adverse reactions observed in a clinical trial of RVVC were headache, abdominal pain, diarrhea, nausea, urinary tract infection and fatigue

To report SUSPECTED ADVERSE REACTIONS, contact SCYNEXIS, Inc. at 1‑888‑982‑SCYX (1‑888‑982‑7299) or FDA at 1‑800‑FDA‑1088 or www.fda.gov/medwatch.

  • BREXAFEMME is contraindicated during pregnancy and in patients with a history of hypersensitivity to ibrexafungerp
  • BREXAFEMME administration during pregnancy may cause fetal harm based on animal studies. Prior to initiating treatment, verify pregnancy status in females of reproductive potential and advise them to use effective contraception during treatment
  • When administering BREXAFEMME with strong CYP3A inhibitors, the dose of BREXAFEMME should be reduced to 150 mg twice a day for one day. Administration of BREXAFEMME with strong CYP3A inducers should be avoided
  • Most common adverse reactions observed in clinical trials (incidence ≥2%) were diarrhea, nausea, abdominal pain, dizziness, and vomiting

To report SUSPECTED ADVERSE REACTIONS, contact SCYNEXIS, Inc. at 1-888-982-SCYX (1-888-982-7299) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

To report SUSPECTED ADVERSE REACTIONS, contact SCYNEXIS, Inc. at 1-888-982-SCYX (1-888-982-7299) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information and Patient Information.

References

1. BREXAFEMME. Prescribing Information. SCYNEXIS, Inc.; 2021. 2. Data on file. SCYNEXIS, Inc., Jersey City. NJ.

Important Safety Information

Indication

/ / / /
BREXAFEMME is contraindicated in pregnancy because it may cause fetal harm based on findings from animal reproductive studies. For females of reproductive potential, verify that the patient is not pregnant prior to initiating treatment. Reassessing pregnancy status prior to each dose is recommended when BREXAFEMME is used monthly for 6 months for reduction in the incidence of recurrent vulvovaginal candidiasis (RVVC). Advise females of reproductive potential to use effective contraception during treatment of vulvovaginal candidiasis (VVC) and throughout the 6-month treatment period for reduction in the incidence of RVVC with BREXAFEMME and for 4 days after the last dose.